Professor and Chair, Department of Radiation Oncology. @MayoRadOnc Opinions stated are my own. Like/RT ≠ endorsement
Mayo Cinic
Joined November 2013
- Tweets420
- Following258
- Followers1.1K
- Likes868
Nadia Laack, MD, MHCDS, MS retweeted
One of my favorite things about Paul Brown’s tweets (other than their high clinical impact of course!) is the classic blue background and yellow text which is a known sign of brilliance and old school awesomeness
🚨🚨Randomized Trial #ASTRO26 Small Cell Lung Cancer Brain Met fractionated SRS vs HA-WBRT 🚨
• No diff time to cognitive failure, neurologic death
• SRS ↑↑ OS
• ↑↑ AEs HA-WBRT
• SRS standard of care SCLC brain met
2/2 sharing the culmination of >15 years of effort to demonstrate the value of comprehensive local therapy for metastatic Ewing sarcoma. Grateful to @COGorg for support and @ASTRO_org #ASTRO2026 for highlighting pediatric cancer on the center stage @MayoCancerCare @MayoRadOnc
1/2 Two career highlights in one day: sharing the stage with my mentor, @PDBrownOnc Dr Paul Brown @ASTRO_org #ASTRO2026
Nadia Laack, MD, MHCDS, MS retweeted
We couldn’t be more proud of our @MayoRadOnc colleagues and the teams from @WashUMedRadOnc, @RadOncUSZ, @MSK_RadOnc, @RadOncUH, @MAASTROclinic, and @MGBResearchNews—and of the incredible accomplishments they have achieved together.
Let's continue rockin' it! 🌟💫
Always energized after meeting up with my Mayo Peds RadOnc colleagues at COG in Chicago @MayoAZRadOnc @MayoCancerCare @MayoFL_RORes @MayoRadOnc
Nadia Laack, MD, MHCDS, MS retweeted
Today’s collaboration announcement between @MayoClinic and @Merck matters to me because it reflects how we’re rethinking drug discovery and precision medicine.
@MayoClinicPlatform
Today, Mayo Clinic and @Merck announced a research and development collaboration to advance AI-enabled drug discovery and precision medicine, accelerating discoveries that improve care for patients worldwide.
The collaboration leverages Mayo Clinic Platform to integrate global clinical expertise, multimodal data and advanced analytics to support early-stage drug discovery and development. Initial areas of focus include neurology, gastroenterology and dermatology.
The agreement positions Mayo Clinic as a global leader in platform-based collaboration, applying AI and clinical insight to advance precision medicine and strengthen the path from discovery to patient care.
Learn more: mayocl.in/4c6Pymd
Congratulations to Dr @SamirPatelMD, our colleague @MayoClinic Arizona, Dr. Ma, and our friends at MDACC for this important work demonstrating the value of proton therapy in oropharyngeal cancer. @MayoCancerCare @MayoRadOnc @MDAndersonNews
newsnetwork.mayoclinic.org/d…
Nadia Laack, MD, MHCDS, MS retweeted
Great to have @lauren_henke and @APrice_BeamOn share their expertise and experience with MRI and CBCT-based online adaptive radiation therapy with our department. @MayoRadOnc
Nadia Laack, MD, MHCDS, MS retweeted
Come to @ACRORadOnc to see more of my flight attendant outfits 😆
…and to learn about HCC with legendary @ldawsonmd !!!
Dr. @yazshaz has a preview of the #ACRO2026 GI session with @ldawsonmd from @UofTDRO! Don't miss this talk on hepatocellular carcinoma -- register at acro.org/annualmeeting & we'll see you in FL in February.
#RadiatingExcellence @ACROresident @RadoncROVER @S_W_R_O @QuadShotNews
Congratulations to our AI team for winning TWO #VIBEsummit awards for their work developing tools detect prostate cancer recurrence and reduce provider burden with automated daily summaries and trial matching. So proud of this incredible team! @MayoRadOnc @MayoCancerCare
Of 3300 physicians and scientists, Dr Paul Brown, my colleague and mentor, was recognized as one of three clinicians of the year at Mayo Clinic Rochester 400+ publications, 4-time teacher of the year, mentor to countless trainees, and dedicated and compassionate clinician
All-Star rad onc, chief resident, and most importantly mom extraordinaire- your mom would be proud. Welcome to the family 💗@MayoRadOnc
🚨Life update🚨
Absolutely thrilled to announce that I have the privilege of staying on as faculty at @MayoRadOnc next year!
All because of you, Mom ❤️
Grateful for my heme & peds supporters @n_laack @wgbreen @AnitaMahajanMD @ScottLesterMD @RomanKowalchuk
Our own Dr Sharifzadeh’s work on direct-to-unit simulation and adaptive SBRT highlighted in the ASTRO news today. Excellent local control and outcomes while improving access for those at a distance from radiation care @MayoRadOnc @MayoCancerCare
Congratulations to Dr Sherry and others who received the Radiation Oncology Institute awards for their research @MayoRadOnc @MayoCancerCare
Nadia Laack, MD, MHCDS, MS retweeted
#ASTRO25 SCAROP meeting. Good turnout.
Interesting lineup from most junior as Chair to most senior. A number of chairs >15 years and counting.
Nice to hear from some of the innovators and those helping push field forward.
Too many to tag
Nadia Laack, MD, MHCDS, MS retweeted
Congrats to @DavidRoutmanMD @KatieVanAbelMD @LindaXYinMD and our stellar MS4 Cecelia Hidalgo for presenting our real world data with DART (30-36 Gy) for HPVOPC.
282 patients and 97% PFS for int risk group. DART is a standard tx for int risk pts @MayoCancerCare
#ASTRO25
Nadia Laack, MD, MHCDS, MS retweeted
Congratulations to the #ASTRO25 ROI Publication Excellence Award winners:
- John Nikitas, MD
- Rituraj Upadhyay, MD
- Ethan Ludmir, MD, Alexander Sherry, MD, and Chad Tang, MD
@JNikitasMD @aiims2738 @ebludmir @AlexSherryMD @ChadTangMD
Nadia Laack, MD, MHCDS, MS retweeted
👏 Outstanding, balanced review by @MartinTomMD calling out #Vorasidenib hype in INDIGO (RCT of Vorasidenib vs Placebo for low grade glioma (LGG) patients with gross disease (i.e. high-risk LGG)
INDIGO data (IDH-mut LGG):
▶️ORR: 0% CR, 1% PR, 10% MR, 83% SD
▶️23% grade ≥3 tox (mostly ↑ LFTs)
▶️Never compared to RT+PCV/TMZ - only placebo
▶️Cross-over allowed (placebo patients were deprived standard of therapy chemoRT twice [at randomization, and at progression]
▶️82% placebo patients progressed at 2 years (these patients should NOT have been observed in the first place)
▶️Short follow-up (14 mo.)
RT toxicities in LGGs often overstated, especially in the context of modern RT techniques (IMRT, VMAT, protons):
🔷️Radiation necrosis ~2%
🔷️Absolute risk of stroke is exceedingly low
🔷️Hormone dysfunction only with significant hypothalamic/pituitary dose (and is a fixable issue); uncommon with modern conformal RT
🔷️Prospective cognitive studies: most show no sustained decline; when seen, often due to tumor progression, not RT
👉 Painting RT as a toxic treatment for LGGs while overselling modest to negligible INDIGO results is misleading for patients and physicians
#ASTRO25 #RadOnc #NeuroOnc
My mentee and future pediatric radonc leader Dr McKone’s fantastic presentation demonstrating improved targeting and risk stratification for pediatric neuroblastoma #ASTRO25 @MayoRadOnc @MayoCancerCare
